Investing.com - Financial Markets Worldwide

Supernus Pharmaceuticals Inc (SUPN)

NASDAQ
Symbol
Exchange
Currency
41.06
+0.02(+0.05%)
-Closed.
Currency in USD
Pre Market
39.82
-1.24(-3.02%)
- Real-time Data
  • Volume:
    198,120
  • Day's Range:
    40.57 - 41.56
  • 52 wk Range:
    24.95 - 41.69

SUPN Overview

Prev. Close
41.04
Day's Range
40.57-41.56
Revenue
499.91M
Open
41.11
52 wk Range
24.95-41.69
EPS
0.705
Volume
198,120
Market Cap
2.22B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
377,651
P/E Ratio
58.16
Beta
0.964
1-Year Change
39.9%
Shares Outstanding
54,058,138
Next Earnings Date
Feb 28, 2023
What is your sentiment on Supernus?
or
Market is currently closed. Voting is open during market hours.

Supernus Pharmaceuticals Inc News

Supernus Pharmaceuticals Inc Analysis

Supernus Pharmaceuticals Inc Company Profile

Supernus Pharmaceuticals Inc Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
603
Market
United States

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. It is also developing a range of CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced Parkinson's disease (PD).

Read More

Income Statement

Analyst Price Target

Average41.50 (+1.07% Upside)
High45.00
Low38.00
Price41.06
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsSellStrong SellBuyStrong BuyStrong Buy
SummaryNeutralNeutralStrong BuyStrong BuyStrong Buy

Trending Stocks

Trending Stocks

Name
Last
High
Low
Chg.
Chg. %
Vol.
Time
Meta Platforms
147.30147.51143.30+5.80+4.10%25.35MNASDAQ
Coca-Cola
60.8161.1060.57-0.12-0.20%11.67MNYSE
McDonald’s
274.72274.75271.70+1.72+0.63%2.22MNYSE
American Express
155.88158.23154.29-0.89-0.57%3.62MNYSE
Chevron
187.79187.81183.48+8.71+4.86%14.00MNYSE
JPMorgan
139.98140.06138.36+0.86+0.62%7.37MNYSE
Goldman Sachs
354.97355.00349.52+5.34+1.53%1.90MNYSE
Intel
30.0930.1129.33+0.39+1.31%46.35MNASDAQ
Tesla
160.27161.42154.76+15.84+10.97%232.88MNASDAQ
Visa A
224.71227.08223.67-0.19-0.08%6.72MNYSE
Netflix
364.87369.02361.70-3.09-0.84%7.62MNASDAQ
HCA
254.85255.60249.47+1.21+0.48%1.80MNYSE
Exxon Mobil
117.76117.78114.33+4.55+4.02%20.91MNYSE
Microsoft
248.00248.31242.00+7.39+3.07%33.13MNASDAQ
Colgate-Palmolive
75.5375.8175.12-0.24-0.32%3.73MNYSE
  • good fundamentals, discount price, solid company. Nice price to add @ 25,20?
    0
    Show previous replies (2)
    • Josef Kurzmannwhat do you find it was not good in the last report?
      0
    • declining earnings and revenues compared to the prior quarter.
      0
    • i know if the earnings and revenues decline for 1 quarter it isn't a big thing but what will happen if they decline for 2 or 3 quarters, we would possible see $15
      0
  • i sold a couple of days ago, seems like the real market crash is finally coming. I'll re-visit SUPN in a couple of months and decide if the share price fell deep enough.
    3
    • yesterday i sent this stock as an "tip" to some stock advisors and hedge funds (only about 5 combined). the price rose 4.38% and today it is up 3.39% in the pre-market. i will tell more fund managers about this stock and then the price should jump really quick.
      3
      • That moment when Josef thinks he is moving markets 😂
        1
    • one more time:I don't have the knowledge to make an educated guess if the FDA will or will not approve the new ADHD treatment and i am pretty sure you don't have the knowledge and insight eigther.What i know if that SUPN had a great balance sheet, is growing it's revenues 30% per year/earnings 40% per year both since 2016. I also know that their P/E ratio is at 12.5. so i can tell you, even if the new drug doesn't get approved the stock should be at around $90 per share (4.5 billion market cap). Right now it is at $30. If the new drug gets approved it should easily be at $100+ by the end of next year (December 2022) that is a 200%+ return in 23 months.
      1
      • BBRW
        1
    • supernus has a great risk/reward ratio. since 2016 earnings and revenues more than doubled yet the stock price is down 50% ($30 as I'm writing) . revenues and earnings are growing very fast (30%/40%p.a.) and this all makes it very likely that this stock quadrouples over the next 3-5 years.
      1
      • and i didn't even factor in that they have a new revolutionary treatment for ADHD in trial 3 that could be approved by the FDA (then the stock would be worth even more).
        1